ABSTRACT
Parkinson’s disease (PD) is a neurodegenerative disorder primarily affecting the dopaminergic neurons in the nigrostriatal pathway (1-3). Supplementation of the dopaminergic system with levodopa treatment was a major breakthrough in the treatment of PD (4,5). However, levodopa-induced motor complications and narrowing of the levodopa therapeutic window over time has limited treatment benefits for many patients with PD (6,7). The development of dopamine receptor agonists has provided an important pharmacotherapeutic strategy for the treatment of PD. Pramipexole (Mirapex®), one such agent, is the subject of this chapter.
